Lv0
0 积分 2024-03-27 加入
Long-term survival of an ALK fusion lung adenocarcinoma patient with high mutation burden and microsatellite instability high: a case report
13分钟前
已完结
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
2个月前
已完结
Réarrangement de ALK dans le cancer pulmonaire non à petites cellules
1年前
已关闭
皖公网安备34019202002308
